Fewer than a tenth of individuals eligible to benefit from GLP-1 drugs including Wegovy can access them, warns the World Health Organization as it publishes its initial guidance on the drugs.
With in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for increased and just access to GLP-1 medication.
According to forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"The new guidelines recognises that excess weight is a lifelong illness that can be treated with holistic and lifelong support," stated its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are major barriers to universal access to the treatments that can aid individuals in losing considerable body mass, says the body.
Weight-Loss Drug Supply Crisis
Despite the present most favorable case, the production of these medications could only cover around 100 million people – under 10% of the global need, as stated by the health organization.
The advice encourages nations and manufacturers to widen access, through measures including licensing agreements.
Exclusive production rights on semaglutide – the main component of the drug Wegovy – is set to lapse in a number of countries in 2026.
The Way Weight-Loss Drugs Function
GLP-1 drugs imitate a biological compound to slow digestion, curb appetite and boost satiety so individuals reduce food intake.
Individuals usually see weight reduction in the initial weeks of beginning the once-weekly jabs.
Evidence suggests patients may see weight return after a year of halting the treatment, when their typical hunger resume.
To be above a healthy weight increases your chance for contracting health problems, such as diabetes, heart disease, stroke, and certain cancers.
Obesity concerns individuals in countries worldwide and was linked to millions of fatalities worldwide in 2024, per the health agency.
